Nissay Asset Management Corp Japan ADV Makes New Investment in Natera, Inc. $NTRA

Key Points

• Nissay Asset Management Corp Japan ADV acquired 15,064 shares of Natera, Inc., valued at approximately $2.13 million, as reported in its recent 13F filing.
• Institutional investors hold 99.90% of Natera's stock, with notable increasing positions from firms like Price T Rowe Associates (up 56.3%) and SG Americas Securities (up 8,233.5%).
• Natera's latest earnings report revealed a loss of ($0.74) per share, missing estimates, but the company reported a 32.2% increase in revenue year-over-year, amounting to $546.6 million.

Nissay Asset Management Corp Japan ADV purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 15,064 shares of the medical research company's stock, valued at approximately $2,130,000.

Several other institutional investors and hedge funds also recently made changes to their positions in NTRA. Price T Rowe Associates Inc. MD boosted its stake in shares of Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company's stock valued at $1,490,144,000 after purchasing an additional 3,795,315 shares in the last quarter. Nuveen LLC acquired a new position in Natera during the 1st quarter worth about $113,375,000. JPMorgan Chase & Co. lifted its position in Natera by 9.9% during the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company's stock worth $1,041,055,000 after buying an additional 660,538 shares in the last quarter. SG Americas Securities LLC lifted its position in Natera by 8,233.5% during the 1st quarter. SG Americas Securities LLC now owns 397,924 shares of the medical research company's stock worth $56,270,000 after buying an additional 393,149 shares in the last quarter. Finally, Maverick Capital Ltd. lifted its position in Natera by 19.7% during the 1st quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company's stock worth $231,173,000 after buying an additional 268,715 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Insider Buying and Selling at Natera

In other Natera news, Director Rowan E. Chapman sold 2,750 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the completion of the transaction, the director owned 6,015 shares of the company's stock, valued at $1,004,444.85. This represents a 31.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gail Boxer Marcus sold 2,496 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $133.17, for a total value of $332,392.32. Following the transaction, the director directly owned 5,763 shares of the company's stock, valued at approximately $767,458.71. This trade represents a 30.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,423 shares of company stock worth $8,459,656 in the last quarter. Company insiders own 5.63% of the company's stock.

Natera Stock Performance

NASDAQ:NTRA traded down $5.30 on Friday, hitting $168.51. 853,083 shares of the stock were exchanged, compared to its average volume of 1,469,458. The stock has a market capitalization of $23.13 billion, a price-to-earnings ratio of -88.23 and a beta of 1.68. Natera, Inc. has a 52 week low of $117.27 and a 52 week high of $183.00. The company's 50-day moving average price is $155.04 and its 200 day moving average price is $154.09.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). The company had revenue of $546.60 million during the quarter, compared to the consensus estimate of $476.84 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business's revenue was up 32.2% compared to the same quarter last year. During the same period last year, the company earned ($0.30) earnings per share. Natera has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

NTRA has been the topic of several research reports. Evercore ISI upgraded shares of Natera to a "strong-buy" rating and set a $170.00 price target on the stock in a research report on Monday, July 28th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Morgan Stanley reiterated an "overweight" rating and set a $195.00 price target on shares of Natera in a research report on Sunday, August 10th. Barclays reissued an "overweight" rating and set a $210.00 price objective (up from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Piper Sandler reissued an "overweight" rating and set a $220.00 price objective (up from $210.00) on shares of Natera in a report on Monday, August 11th. One investment analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $194.00.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.